<DOC>
	<DOCNO>NCT01387087</DOCNO>
	<brief_summary>The objective study explore safety tolerability single ascending dos ASP015K , establish maximum tolerated dose , determine pharmacokinetics pharmacodynamics healthy volunteer .</brief_summary>
	<brief_title>A Study Assess Safety , Tolerability Pharmacokinetics ASP015K</brief_title>
	<detailed_description>Subjects confine clinical research unit five day . Some subject participate two confinement period . Subjects receive follow-up phone call ass safety seven day administration single dose study drug . Subjects assign one nine sequential group A , B , C , D , E , F , G , H , I . In group , 6 subject randomize ASP015K 2 subject randomize placebo . Subjects group F participate two treatment period . Subjects first treatment period group F single study drug dose administer fasted state . Subjects second treatment period group F single study drug dose administer immediately follow standard FDA recommend high-fat breakfast .</detailed_description>
	<criteria>If female , subject least 2 year post menopausal surgically sterile per documentation provide third party medical professional subject pregnant document negative serum pregnancy test If male , subject agree sexual abstinence and/or use highly effective method birth control study period Subject medically healthy , clinically significant abnormality medical history abnormality observe upon physical examination 12 lead electrocardiogram ( ECG ) Subject 's fast clinical laboratory value within normal limit Subject nonsmoker use tobacco minimum 3 month Subjects must weigh least 45 kg Body Mass Index ( BMI ) 1832 kg/m2 Subject positive test hepatitis C antibody , positive hepatitis B surface antigen ( HBsAg ) Subject history human immunodeficiency virus ( HIV ) antibody Subject history severe allergic anaphylactic reaction Subject history chronic diarrhea Subject vaccinate within last 60 day prior study drug administration Subject previous history clinically significant neurological , gastrointestinal , renal , hepatic , pulmonary , metabolic , cardiovascular , psychiatric , endocrine , hematological disorder disease , medical condition , Investigator 's opinion , would preclude participation study Subject clinically significant illness within 1 month prior study drug administration Subject history hemorrhoid Subject history drug alcohol abuse positive urine screen alcohol drug abuse and/or illegal drug Subject treatment prescription medication ( except hormone replacement therapy acetaminophen ) , complementary alternative medicine ( CAM ) within 14 day , overthecounter product within 1 week , alcohol , caffeine grapefruit juice within 24 hour prior study drug administration Subject treatment another investigational drug approve therapy investigational use within 30 day 10 halflives , whichever longer , prior study drug administration participate prior group current study Subject history blood donation within 30 day prior study drug administration donate plasma within 7 day prior study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>ASP015K</keyword>
	<keyword>Healthy subject</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Maximum tolerate dose</keyword>
</DOC>